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Objectives The purpose of this study was to examine the association between prolongation of QT interval corrected for
heart rate (QTc) with incident stroke.
Background Unlike cardiovascular morbidity and mortality, little is known about the relationship between QTc and risk of
stroke.
Methods A total of 27,411 participants age 45 years and older without previous stroke from the REGARDS (REasons for
Geographic and Racial Differences in Stroke) study were included in this analysis. QTc was calculated using Fra-
mingham formula (QTcFram). Stroke cases were identified and adjudicated during up to 8.2 years of follow-up
(median, 5.1 years).
Results The risk of incident stroke in study participants with prolonged QTcFram was almost 3 times the risk in those with nor-
mal QTcFram (hazard ratio [HR] [95% confidence interval (CI)]: 2.88 [2.12 to 3.92], p  0.0001). After adjustment for
demographics (age, race, and sex), traditional stroke risk factors (antihypertensive medication use, systolic blood
pressure, current smoking, diabetes, left ventricular hypertrophy, atrial fibrillation, and previous cardiovascular dis-
ease), warfarin use, aspirin use, QRS duration and use of QTc-prolonging drugs, the risk of stroke remained signifi-
cantly high (HR [95% CI]: 1.67 [1.16 to 2.41], p  0.0061) and was consistent across several subgroups of REGARDS
study participants. Similar results were obtained when the risk of stroke was estimated per 1-SD increase in QTcFram,
(HR [95% CI]: 1.12 [1.03 to 1.21], p  0.0053 in multivariable-adjusted model) and when other QTc correction formu-
las including those of Hodge, Bazett, and Fridericia were used.
Conclusions QTc prolongation is associated with a significantly increased risk of incident stroke independent of traditional stroke
risk factors. Examining the risk of stroke associated with QTc-prolonging drugs may be warranted. (J Am
Coll Cardiol 2012;59:1460–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.025The association between QT interval corrected for heart
rate (QTc) and cardiovascular morbidity and mortality is
well established (1–4). Little is known, however, about the
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20, 2011, accepted January 3, 2012.relationship between this simple electrocardiographic
(ECG) marker and incident stroke.
Prolonged QTc has been reported in 38% to 71% of
patients during acute stroke, constituting the most frequent
single ECG abnormality in this setting (5). The pathophys-
iology behind this phenomenon has not been elucidated.
Autonomic dysregulation caused by overactivity of the
sympathetic nervous system during acute stroke has been
suggested as one of the potential mechanisms (6). Never-
theless, it is also possible that in some cases, prolonged QTc
actually existed before the development of stroke, and its
presence during the acute phase reflects its common pres-
ence in individuals at risk; hence, it could be used as a
marker for future stroke. Further, prolonged QTc is asso-
ciated with several cardiovascular disease (CVD) risk factors
including advanced age, impaired glucose homeostasis,
smoking, left ventricular hypertrophy (LVH), and high
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stroke. Therefore, it is plausible that QTc has prognostic
value for prediction of future stroke. This contention is
supported by a small study from Brazil that included 471
individuals with diabetes (9) and in a group from a general
Japanese population (10), but no data exist from U.S. or European
population-based studies.
We sought to examine the risk of incident stroke associ-
ated with prolongation of QTc in the REGARDS (REa-
sons for Geographic and Racial Differences in Stroke) study.
With its biracial population, centrally read ECG data,
physician-adjudicated stroke events, and long-term follow-up,
the REGARDS study provides a unique opportunity to
address our research questions.
Methods
Study population. The goals and design of the RE-
GARDS study were published elsewhere (11). Briefly, the
study was designed to investigate the causes of regional and
racial disparities in stroke mortality, oversampling blacks
and residents of the southeastern stroke belt region (North
Carolina, South Carolina, Georgia, Alabama, Mississippi,
Tennessee, Arkansas, and Louisiana). Individuals were re-
cruited from a commercially available list of residents using
a combination of postal and telephone contact with a 49%
cooperation rate. Using a computer-assisted telephone in-
terview, trained interviewers obtained demographic infor-
mation and a cardiovascular medical history. Consent was
obtained initially on the telephone and subsequently in
writing during an in-person evaluation. In-home brief
physical examinations were conducted 3 to 4 weeks after the
telephone interview. Participants are followed every 6
months by telephone for possible stroke outcomes.
Of the 30,239 REGARDS participants enrolled between
2003 and October 2007, we excluded 1,930 participants
reporting previous stroke, 359 with no or poor quality ECG
data, and 539 with no follow-up data, resulting in 27,411
(91%) participants for analysis.
The institutional review boards of each participating
center reviewed and approved the study methods.
QT interval corrected for heart rate. Baseline resting
electrocardiograms were recorded during in-home visits.
ECG tracings were mailed for reading and coding at a
central electrocardiography core laboratory located at the
Epidemiological Cardiology Research Center (EPICARE),
Wake Forest School of Medicine, Winson-Salem, North
Carolina. To calculate QTc from the uncorrected QT and
heart rate, we followed the recommendations of the Amer-
ican Heart Association, American College of Cardiology,
and Heart Rhythm Society for the Standardization and
Interpretation of the Electrocardiogram (12). In this con-
text, we used the Framingham linear regression formula:
[QTcFram  QT  154 (1  60/heart rate)], where
TcFram is QTc calculated using the Framingham formula
(13). QTcFram values of 460 ms in women and 450 msin men were considered abnor-
mal (i.e., prolonged QTcFram)
(12). As secondary analysis to
confirm the results and to pro-
vide comparability with previous
studies, we also used other tradi-
tional QTc correction methods
including those of Hodge (14)
[QTcHod  QT  1.75 (heart
ate  60)], where QTcHod is
QTc calculated using the Hodge
formula; Bazett (15) [QTcBaz
T (heart rate/60)1/2], where
QTcBaz is QTc calculated using
the Bazett formula; and Fridericia
[QTcFrid  QT (heart rate/60)
1/3],
here QTcFrid is QTc calculated
using the Fridericia formula (16).
Stroke events. Report of a pos-
sible stroke/transient ischemic
attack or a positive response to
the stroke symptoms on the
Questionnaire for Verifying
Stroke-Free Status (17), result-
ing in hospitalization, during
follow-up generated a request for
retrieval of medical records that were centrally adjudicated
by a panel of stroke expert physicians. Stroke events were
defined according to the World Health Organization defi-
nition as “rapidly developing clinical signs of focal, at times
global, disturbance of cerebral function, lasting more than
24 hours or leading to death with no apparent cause other
than that of vascular origin” (18). Events not meeting the
World Health Organization definition but characterized by
symptoms lasting24 h with neuroimaging consistent with
acute ischemia or hemorrhage were classified as clinical
strokes. Strokes were further classified as ischemic or hem-
orrhagic. This analysis included World Health Organiza-
tion–defined as well as clinical ischemic or hemorrhagic
fatal and nonfatal stroke cases. As secondary analysis, we
used ischemic stroke only excluding hemorrhagic strokes.
Further details on stroke identification and adjudication in
the REGARDS study are available elsewhere (19).
Other variables. Standardized physical measures that in-
cluded height, weight, and blood pressure were collected at
the in-home physical examination. Demographics (age, sex,
and race) were defined by self-report. Traditional stroke risk
factors were selected based on the components of the
Framingham Stroke Risk Score, which includes antihyper-
tensive medication use, systolic blood pressure, current
smoking, diabetes, LVH, atrial fibrillation (AF), and pre-
vious CVD (20). History of stroke was defined by self-
report of a physician diagnosis, and previous CVD was
similarly defined by self-report (myocardial infarction or
heart attack, coronary artery bypass surgery, coronary an-
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
CVD  cardiovascular
disease
ECG  electrocardiographic
HR  hazard ratio
LVH  left ventricular
hypertrophy
QTc  QT interval
corrected for heart rate
QTcBaz  QT interval
corrected for heart rate
using the Bazett formula
QTcFram  QT interval
corrected for heart rate
using the Framingham
formula
QTcFrid  QT interval
corrected for heart rate
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cardiographic Sokolow-Lyon criteria (21). AF was defined
based on ECG diagnosis and/or self-report of a previous
physician diagnosis, as detailed elsewhere (22). Use of antihy-
pertensive medications, current warfarin treatment, aspirin use,
and use of QTc-prolonging drugs were defined using an
inventory of current medications that was conducted during
the in-home visits; all prescription and over-the-counter med-
ications taken in the past 2 weeks were recorded.
Statistical analysis. Frequency distributions of all variables
were first inspected to identify anomalies and outliers
possibly caused by measurement artifacts. Continuous data
were described by their mean and SD and categorical data as
proportions (percentage). Differences in characteristics by
QTc-prolongation status were assessed by chi-square (for
categorical variables) and unpaired t (for continuous vari-
bles) tests.
Cox proportional hazards analysis was used to estimate
he hazard ratios (HRs) for incident stroke associated with
TcFram per 1-SD increase, as well as prolonged versus
normal, separately, in a series of incremental models as
follows: first unadjusted (model 1); then adjusted for demo-
graphics (age, sex, and race) (model 2); then additionally
adjusted for traditional stroke risk factors (antihypertensive
medication use, systolic blood pressure, current smoking,
diabetes, LVH, AF, and previous CVD) (model 3); and
finally additionally adjusted for QRS duration, QTc-
prolonging drugs, warfarin use, and aspirin use (model 4).
The assumptions of the Cox proportional hazards models
were examined by plotting the natural log of the cumulative
hazard of stroke by the natural log of time. Multiple
Baseline Characteristics of the REGARDS StudyTable 1 Baseline Characteristics of the REG
Characteristic*
Total Popu
(N  27,4
Age, yrs 64.7 9
African American, % 40.3
Men, % 44.7
Body mass index, kg/m2 29.3 6
Current smoking, % 14.2
History of cardiovascular disease, % 16.7
Family history of cardiovascular disease, % 57.2
Diabetes, % 20.9
Hypertension, % 57.8
Atrial fibrillation, % 8.3
Left ventricular hypertrophy, % 9.6
Antihypertensive medication use, % 57.1
QTc-prolonging drug use, % 24.4
Warfarin use, % 3.1
Aspirin use, % 42.2
Systolic blood pressure, mm Hg 127.3 1
Heart rate, beats/min 66.7 1
QRS duration, ms 87.4 1
Uncorrected QT interval, ms 395.6 3
QTcFram interval, ms 407.2 2*Continuous variables are reported as mean (SD). †Defined as values of 4
QTc  QT interval corrected for heart rate; QTcFram  QT interval correctedimputation techniques for incident stroke were used in the
analysis to reduce the potential bias introduced through
either failure to retrieve medical records or from records
remaining in the adjudication process at the time of
analysis. Additional details of the application of multiple
imputation techniques in the REGARDS study are provided
elsewhere (23).
Secondary analyses included: 1) examining the associa-
tion between QTcFram and incident stroke across different
subgroups of the study participants stratified by age, sex,
race, smoking status, hypertension, diabetes, LVH, previous
CVD, AF, and QRS duration; 2) examining interaction
between each of sex and race with QTcFram for prediction
of stroke; 3) using ischemic stroke only as an outcome
instead of both ischemic and hemorrhagic; and finally
4) using QTcHod, QTcBaz, and QTcFrid, separately, in-
stead of QTcFram in the proportional hazards models.
esults
t baseline, the average QTcFram interval duration was
407  23 ms, with 740 of the participants (2.7%) having
prolonged QTcFram. Table 1 shows the characteristics of the
study population, overall and stratified by presence of
prolonged QTcFram. Compared with those with normal
QTcFram, participants with prolonged QTcFram were older,
ith fewer blacks and more males. Previous CVD, diabetes,
F, LVH, and use of QTc-prolonging drugs were more
revalent in the prolonged QTcFram group.
During up to 8.2 years of follow-up (median 5.1 years), 608
total strokes occurred, of which 491 were ischemic strokes.
icipants, 2003 to 2007S Study Participants, 2003 to 2007
Prolonged QTcFram†
(n  740)
Normal QTcFram
(n  26,671) p Value
70.1 9.65 64.5 9.34 0.0001
36.5 40.4 0.0332
62.2 44.2 0.0001
29.4 6.13 29.3 6.18 0.8162
12.5 14.2 0.0205
43.2 16.0 0.0001
58.7 57.2 0.4513
29.3 20.7 0.0001
75.4 57.3 0.0001
21.0 7.9 0.0001
20.1 9.3 0.0001
79.2 56.5 0.0001
31.6 24.3 0.0001
11.0 2.9 0.0001
57.5 41.8 0.0001
131.7 18.48 127.2 16.47 0.0001
66.5 10.91 66.71 11.40 0.6989
123.8 25.63 86.4 13.79 0.0001
459.0 30.39 393.9 31.07 0.0001
470.4 19.10 405.4 20.84 0.0001PartARD
lation
11)
.40
.18
6.55
1.39
5.61
2.80
3.3060 ms in women and 450 ms in men (12).
for heart rate using the Framingham formula.
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April 17, 2012:1460–7 QTc and Stroke: The REGARDS TrialStroke developed in 5.4% of participants with prolonged
QTcFram compared with only 2.8% of those with normal
TcFram (p  0.0001). Figure 1 shows the event-free survival
urves of participants with and without prolonged QTcFram.
As shown in Table 2, for every 1-SD increase in QTcFram,
here was 24% increase in the risk of incident stroke (HR
95% confidence interval (CI)]: 1.24 [1.16 to 1.33],
 0.0001). This association remained statistically signif-
icant after adjustment for demographics, traditional stroke
risk factors, warfarin use, aspirin use, QRS duration, and use
of QTc-prolonging drugs (HR [95% CI]: 1.12 [1.03 to
1.21], p  0.0053). Similar results were observed when
QTcHod, QTcBaz, and QTcFrid separately were used instead of
the QTcFram in the proportional hazards models (Table 2).
Figure 1
Kaplan-Meier Curves for
Incident Stroke in the REGARDS Study
Participants With and Without Prolonged QTcFram
The horizontal axis shows follow-up time in years, and the vertical axis the pro-
portion of the population stroke free for those without (red line) and with
(green line) prolonged heart rate–corrected QT interval (QTc). QTcFram  QT
interval corrected for heart rate using the Framingham formula.
Prolongation of QTc and Risk of Incident Stroke in the REGARDS STable 2 Prolongation of QTc and Risk of Incident Stroke in the
Model 1* p Value Model 2† p
HR (95%
QTcFram 1.24 (1.16–1.33) 0.0001 1.18 (1.10–1.27) 0
QTcHod 1.25 (1.16–1.34) 0.0001 1.18 (1.10–1.26) 0
QTcBaz 1.26 (1.18–1.36) 0.0001 1.21 (1.13–1.30) 0
QTcFrid 1.25 (1.17–1.34) 0.0001 1.19 (1.11–1.27) 0
HR (95% CI) Associa
QTcFram 2.88 (2.12–3.92) 0.0001 2.08 (1.52–2.84) 0
QTcHod 2.45 (1.79–3.34) 0.0001 1.81 (1.33–2.48) 0
QTcBaz 2.02 (1.55–2.63) 0.0001 1.56 (1.20–2.04) 0
QTcFrid 2.69 (2.00–3.62) 0.0001 1.95 (1.45–2.63) 0
*Model 1, unadjusted. †Model 2, adjusted for age, race, and sex. ‡Model 3, adjusted for model
smoking, diabetes, left ventricular hypertrophy, atrial fibrillation, and previous cardiovascular disea
drugs. Prolonged QTc defined as 460 ms in women and 450 ms or longer in men.CI  confidence interval; HR  hazard ratio; QTc  QT interval corrected for heart rate; QTcBaz  QT in
rate using the Framingham formula; QTcFrid  QT interval corrected for heart rate using the Fridericia forThe risk of stroke in study participants with prolonged
QTcFram was almost 3 times the risk in those with normal
QTcFram (HR [95% CI]: 2.88 [2.12 to 3.92], p  0.0001).
After adjustment for demographics, traditional stroke risk
factors, warfarin use, aspirin use, QRS duration, and use of
QTc-prolonging drugs, the risk of stroke remained signif-
icantly high (HR [95% CI]: 1.67 [1.16 to 2.41], p 
0.0061). Similar results were observed in the unadjusted and
demographics-adjusted models of the QTcHod, QTcBaz, and
QTcFrid. However, after further adjustment for stroke risk
factors, warfarin use, aspirin use, QRS duration, and use of
QTc-prolonging drugs, the HRs associated with QTcBaz
were no longer statistically significant and were marginal
with QTcHod (Table 2).
Figure 2 shows the multivariable-adjusted HRs for incident
stroke associated with prolonged versus normal QTcFram in
everal subgroups of REGARDS study participants stratified
y age, race, sex, smoking status, hypertension, diabetes, LVH,
F, and QRS duration. As shown, in a model adjusted for
emographics, traditional stroke risk factors, warfarin use,
spirin use, QRS duration, and use of QTc-prolonging drugs,
rolonged QTcFram (vs. normal) was consistently associated
with significantly increased stroke risk across all subgroups
with nonsignificant probability values for interaction.
Demographics adjusted uncorrected QT was marginally
predictive of incident stroke (HR [95% CI]: 1.08 [1.00 to
1.16], p  0.0446 for every 1-SD increase; 1.40 [1.01 to
1.93], p  0.0423] for prolonged vs. normal). However,
these associations were no longer significant after further
adjustment for traditional stroke risk factor (HR [95% CI]:
1.06 [0.99 to 1.15], p 0.1122 for every 1-SD increase and
1.21 [0.86 to 1.70], p  0.2709 for prolonged vs. normal)
and further adjustment for warfarin use, aspirin use, QRS
duration, and use of QTc-prolonging drugs (HR [95% CI]:
1.06 [0.98 to 1.15], p  0.1575 for every 1-SD increase;
1.19 [0.84 to 1.68], p  0.3367 for prolonged vs. normal).
Similarly, in models similar to those used for QTc, heart
ARDS Study
Model 3‡ p Value Model 4§ p Value
r 1-SD Increase in QTc
1.11 (1.04–1.20) 0.0036 1.12 (1.03–1.21) 0.0053
1.12 (1.04–1.20) 0.0031 1.12 (1.04–1.21) 0.0045
1.13 (1.05–1.21) 0.0009 1.14 (1.05–1.23) 0.0013
1.12 (1.04–1.20) 0.0021 1.13 (1.04–1.22) 0.0029
ith Prolonged QTc (vs. normal QTc)
1.64 (1.17–2.28) 0.0040 1.67 (1.16–2.41) 0.0061
1.44 (1.03–2.02) 0.0345 1.43 (1.00–2.05) 0.0521
1.24 (0.94–1.64) 0.1308 1.21 (0.89–1.64) 0.2205
1.53 (1.11–2.11) 0.0088 1.55 (1.09–2.21) 0.0148
traditional stroke risk factors (antihypertensive medication use, systolic blood pressure, current
odel 4, adjusted for model 3 plus warfarin use, aspirin use, QRS duration and use of QTc-prolongingtudyREG
Value
CI) pe
.0001
.0001
.0001
.0001
ted W
.0001
.0002
.0005
.0001
2 plus
se). §Mterval corrected for heart rate using the Bazett formula; QTcFram  QT interval corrected for heart
mula; QTcHod  QT interval corrected for heart rate using the Hodge formula.
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QTc and Stroke: The REGARDS Trial April 17, 2012:1460–7rate alone was not predictive of stroke after adjusting for
traditional stroke risk factors (HR [95% CI]: 1.04 [0.96 to
1.12], p  0.3309 for every 1-SD increase; 0.97 [0.81 to
1.15), p  0.7021 for abnormal vs. normal [60 to 90
eats/min]) and further adjustment for warfarin use, aspirin
se, QRS duration, and use of QTc-prolonging drugs (HR
95% CI]: 1.04 [0.96 to 1.12], p  0.3886 for every 1-SD
ncrease, and 0.97 [0.81 to 1.15], p  0.7182 for abnormal
s. normal [60 to 90 beats/min]).
There were no meaningful differences in the observed
atterns of associations assessing ischemic stroke only (data
ot shown). Also, there was no significant interaction
etween each of sex and race subgroups with QTcFram for
rediction of stroke in the fully adjusted models.
iscussion
n this analysis from a national, U.S. general population, we
howed that QTc prolongation is associated with a signif-
cantly increased risk of incident stroke independent of
raditional stroke risk factors and consistently across differ-
nt demographic and clinical subgroups. These findings add
urther concern regarding the consequences of QTc prolon-
Under 65 Yrs
Over 65 Yrs
Black
White
Female
Male
Current Smoker
Not Current Smoker
Hypertension
No Hypertension
Diabetes
No Diabetes
LVH
No LVH
CVD
No CVD
AF
No AF
QRS Under 100 ms
QRS Over 100 ms
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Hazard Rat
Figure 2 Prolongation of QTcFram and Risk of Incident Stroke W
Hazard ratios are adjusted for demographics (age, race, and sex), traditional stroke ris
betes, left ventricular hypertrophy [LVH], atrial fibrillation [AF], and previous cardiovasc
drugs, as appropriate. Green circles in the graph represent the hazard ratio and lines
within each subgroups was observed. QTcFram  QT interval corrected for heart rate uation. In addition to increased cardiovascular morbidity end mortality (1–4), stroke seems to be another serious
utcome. With the increasing number of QTc-prolonging
rugs (24) and in light of our results, examining the risk of
troke associated with QTc-prolonging drugs may be war-
anted. To our knowledge, no previous studies examined the
ssociation between QTc-prolonging drugs and stroke.
evertheless, the PALLAS (Permanent Atrial Fibrillation
utcome Study Using Dronedarone on Top of Standard
herapy) trial (25) gives an indirect clue of a possible link
etween QTc-prolonging drugs and risk of stroke. In the
ALLAS trial, stroke occurred in 23 patients in the
ronedarone group and in only 10 in the placebo group (HR
95% CI]: 2.32 [1.11 to 4.88], p  0.02). Although it was
not clear how many of the stroke cases in the PALLAS trial
could be explained by the QTc prolonging effect of drone-
darone, it has been noticed that after 1 month of treatment,
there was 8  40 ms increase in the QTc duration in the
dronedarone group versus 2  38 ms in the placebo group
(p  0.001), which is in accord with the known QTc-
rolonging properties of dronedarone. In contrast to the
ALLAS trial results, however, the ATHENA (A placebo-
ontrolled, double-blind, parallel arm Trial to assess the
0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
d 95% Confidence Interval
Subgroups of the REGARDS Study Participants
ors (antihypertensive medication use, systolic blood pressure, smoking status, dia-
sease [CVD]), warfarin use, aspirin use, QRS duration, and use of QTc-prolonging
ent the 95% confidence interval. No significant interaction between the categories
e Framingham formula.4.
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April 17, 2012:1460–7 QTc and Stroke: The REGARDS Trialcardiovascular Hospitalization or death from any cause in
patiENts with Atrial fibrillation/atrial flutter) trial showed
that dronedarone was associated with a lower stroke risk
(26). Whether this discrepancy between PALLAS and
ATHENA could be explained by the type of AF (being
permanent in PALLAS and paroxysmal in ATHENA) or
by differences in the QTc-prolongation is just a speculation
at this stage. Another clue of a potential link between
QTc-prolonging drugs and risk of stroke comes from our
study. In an additional analysis, we observed a 19% increase
in the risk of stroke in participants taking QTc-prolonging
drugs compared with those not taking these drugs, after
adjusting for age, sex, and race (HR [95% CI]: 1.19 [0.99 to
1.42], p  0.059). However, this needs to be investigated
further in a study designed specifically to address this
question.
Two previous studies (9,10), 1 from Brazil on diabetic
population and 1 from Japan, showed a significant relation-
ship between prolongation of QTc and incident stroke,
which is in accord with our results. However, both studies
did not include whites (Caucasians) or blacks (African
Americans), used only the debatable Bazett formula for
calculating QTc, and at least 1 of them was lacking data on
AF, smoking status, and/or QTc-prolonging drugs, which
makes it difficult to reach a convincing conclusion.
In our analysis, the association between QTc and stroke
remained highly significant despite adjustment for tradi-
tional stroke risk factors. Noteworthy, we decided a priori to
focus on traditional stroke risk factors (i.e., components of
the Framingham Stroke Risk Score) and major potential
confounders. Nevertheless, in an additional analysis, we
added other possibly related risk factors to model 4 includ-
ing family history of CVD, chronic kidney disease, and
hypertension (as a categorical variable in addition to systolic
blood pressure and antihypertensive medications, which
were already included in model 4). Further adjustment for
these variables did not result in any significant change in the
risk estimates (results not shown). This means that the
association of QTc with CVD risk factors does not fully
explain the prognostic significance of QTc as a stroke
predictor. It is possible, however, that prolonged QTc
interval is a marker of silent undetected atherosclerotic
vascular disease (9). In 1 study, QTc was significantly
associated with carotid intima media thickness (27) and in
another study with activated factor XII levels (28). In both
studies, the associations of QTc with these markers of
atherosclerotic vascular disease remained significant after
adjustment for other CVD risk factors. This reinforces the
hypothesis that QTc prolongation may be a surrogate
indicator of subclinical atherosclerosis and subsequently can
be predictive of future atherosclerotic vascular events such as
stroke. Studies aimed at clarifying the mechanism by which
QTc is predictive of stroke are needed. Interestingly, the
mechanistic relationship between stroke and LVH (which is
one of the well-established traditional stroke risk factors) is
unclear as well. All that we know is that LVH is associated Ewith several CVD risk factors (which is the same situation
with QTc). Therefore, what has been stated about LVH
and risk of stroke (29) may also be applicable to QTc; that
is, “it is not yet entirely clear whether LVH (or QTc in our
case) represents a marker, a limited adaptive process or a
pathological process.”
The QT interval is heart rate dependent; the faster the
heart rate is, the shorter the QT interval and vice versa.
Therefore, using QTc rather than the uncorrected QT
interval is mandatory. This is further supported by our
findings of a lack of significant stroke risk with uncorrected
QT interval while observing a strong association with QTc.
Many formulas have been proposed to calculate QTc from
the uncorrected QT interval and heart rate. The most
widely used is the nonlinear formula of Bazett (15). How-
ever, recent guidelines of ECG standardization and inter-
pretation (12) recommend using linear regression formulas,
avoiding nonlinear formulas, especially that of Bazett, and
incorporating QRS duration in the models. Subsequently,
we decided to use QTcFram and adjust for QRS duration in
the full model. Nevertheless, to confirm our results and to
provide comparability with other studies, we also used 3
other QTc formulas including the traditional QTcBaz, and
the results were largely consistent. We also examined the
association between heart rate and stroke in models similar
to those we used for QTc, and we did not find significant
associations. This precludes the possibility that the observed
association between QTc and stroke was driven by heart
rate.
As shown, the risk of stroke associated with 1-SD
increase in QTc was consistent across the 4 QTc correction
formulas that we used in our study. However, when we
examined the risk of stroke associated with prolonged QTc
(vs. normal), QTcBaz was not as significantly predictive as
ther formulas in the multivariable models. This observa-
ion is in accord with the current general agreement that
TcBaz can erroneously estimate QTc, which could affect
ts prognostic significance (12). In our study the prevalence
f prolonged QTc (defined as QTc460 ms in women and
450 ms in men) was approximately 5% with the Bazett
ormula and between 2.7% and 3% with the other 3
ormulas. This means that at least 2% of our study partici-
ants were misclassified as having prolonged QTc by the
azett formula, which might have led to the null findings
hat we observed with QTcBaz. The lack of strong prognos-
ic significance of QTcBaz compared with the other QTc
ormulas supports the explicit recommendation of the cur-
ent guidelines to avoid using the Bazett formula (12).
evertheless, because the prognostic significance of QTcBaz
as a continuous variable (i.e., per 1-SD increase) was as
good as other QTc formulas, using different (possibly higher
cut points) to define prolonged QTcBaz may improve its
rognostic significance. In other words, our findings suggest
hat the cut points defining prolonged QTc need to be
ormula specific to avoid masking important relationships.
xamining the impact of differences in the cut points that
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beyond the scope of this paper, which is the reason we
decided to use the cut points suggested by the current
guidelines (12).
Study limitations. Only whites and blacks were included
in the REGARDS study; hence, our results may not be
applicable to other racial/ethnic groups. We could not
differentiate between congenital and acquired (drug-
induced) QTc prolongation. Nevertheless, given the age of
REGARDS study population acquired QTc prolongation is
a more likely etiology.
It remains possible that AF was underdetected in some
cases. Because the antiarrhythmic drugs used in AF can
often prolong the QT interval, 1 potential explanation for
these findings may have been that more participants with
undetected/unreported AF had drug-induced prolongation
of QTc and subsequently an increased risk of stroke.
However, given that AF in our study was ascertained by 2
methods (self-report of a previous physician diagnosis and
study scheduled ECG; both have similar stroke predictive
value [22]), most of AF cases must have been captured.
Also, we adjusted for QTc-prolonging drugs in our analysis,
which preclude the possibility of the confounding effect of
antiarrhythmic drugs with QTc-prolonging properties.
Data on the use of medications (from which we identified
QTc-prolonging drugs) is based on review of pill bottles
brought by participants during the study baseline. Reporting
medications by the participants may have been incomplete
or may have changed before the incident event leading to
misclassification. However, such inaccuracies or misclassifi-
cation should be randomly distributed across groups and
should not affect the overall conclusions.
Despite these limitations, this is the first report examining
the relationship between QTc prolongation and risk of stroke
in one of the largest biracial, population-based, longitudinal
cohort studies in the United States, the REGARDS study.
Other strengths include central ECG reading, using multiple
QTc correction formulas to confirm the results, and the
substantial accumulating number of physician-adjudicated
stroke events.
Conclusions
Prolongation of QTc is associated with a significantly
increased risk of incident stroke independent of traditional
stroke risk factors. These findings suggest that important
predictive information may be derived from such a simple
ECG marker. With the increasing number of QTc-
prolonging drugs and in light of our results, examining the
risk of stroke associated with QTc-prolonging drugs may be
warranted.
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